[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336876-105":59,"doc-detail-336876-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","fully-automated-artificial-intelligence-solution-for-human-epidermal-growth-factor-receptor-2-immunohistochemistry-scoring-in-breast-cancer-a-multireader-study","Fully Automated Artificial Intelligence Solution for Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Scoring in Breast Cancer - A Multireader Study","","The paper validates a fully automated artificial intelligence solution designed to interpret human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) for breast carcinoma. A two-arm multireader study evaluated 120 HER2 whole-slide images from four sites, comparing four surgical pathologists’ scoring with and without AI against high-confidence ground truth based on ASCO/College of American Pathologists guidelines. Results showed 92.1% agreement on high-confidence cases and improved reader consistency. The AI particularly enhanced discrimination of HER2 0 versus HER2 1+ cases, supporting use as a decision support tool for reproducible scoring and HER2-low identification.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/fully-automated-artificial-intelligence-solution-for-human-epidermal-growth-factor-receptor-2-immunohistochemistry-scoring-in-breast-cancer-a-multireader-study/336876/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/fully-automated-artificial-intelligence-solution-for-human-epidermal-growth-factor-receptor-2-immunohistochemistry-scoring-in-breast-cancer-a-multireader-study/336876.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in HER2 testing?","Question",{"text":112,"@type":113},"The study targets the need for more accurate and reproducible HER2 immunohistochemistry (IHC) scoring to support effective HER2-targeted treatment decisions, especially for HER2-low cancers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the AI solution evaluated in the multireader study?",{"text":117,"@type":113},"A two-arm multireader design assessed 120 HER2 IHC whole-slide images, with four surgical pathologists scoring both without and with AI support. Comparisons were made against high-confidence ground truth derived from expert consensus following ASCO/CAP guidelines.",{"name":119,"@type":110,"acceptedAnswer":120},"What improvements did the AI tool produce for pathologists?",{"text":121,"@type":113},"AI assistance increased interobserver agreement and scoring accuracy versus digital manual review, with particularly strong improvements for distinguishing HER2 0 from HER2 1+ cases.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336876,1790218182,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Original Reports | Biomarkers  \nFully Automated Artiﬁcial Intelligence Solution for Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Scoring in Breast Cancer: A Multireader Study  \nSavitri Krishnamurthy, MD1 ; Stuart J. Schnitt, MD2,3; Anne Vincent-Salomon, MD, PhD4 ; Rita Canas-Marques, MD5; Eugenia Colon, MD6; Kanchan Kantekure, MD7; Marina Maklakovski, MD8; Wilfrid Finck, MD9; Jeanne Thomassin, MD9; Yuval Globerson, MSc10; Lilach Bien, MSc10; Giuseppe Mallel, MD10 ; Maya Grinwald, PhD10; Chaim Linhart, PhD10; Judith Sandbank, MD10,11; and Manuela Vecsler, PhD10   \nDOI [https://doi.org/10.1200/PO.24.00353](https://doi.org/10.1200/PO.24.00353)  \n\n| ABSTRACT |  |\n| --- | --- |\n| PURPOSE | The proven efﬁcacy of human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate therapy for treating HER2-low breast cancers necessitates more accurate and reproducible HER2 immunohistochemistry (IHC) scoring. We aimed to validate performance and utility of a fully automated artiﬁcial intelligence (AI) solution for interpreting HER2 IHC in breast carcinoma. |\n| MATERIALS\u003Cbr>AND METHODS | A two-arm multireader study of 120 HER2 IHC whole-slide images from four sites assessed HER2 scoring by four surgical pathologists without and with the aid of an AI HER2 solution. Both arms were compared with high-conﬁdence ground truth (GT) established by agreement of at least four of ﬁve breast pathology subspecialists according to ASCO/College of American Pathologists (CAP) 2018/2023 guidelines. |\n| RESULTS | The mean interobserver agreement among GT pathologists across all HER2 scores was 72.4%(N 5 120) . The AI solution demonstrated high accuracy for HER2 scoring, with 92.1% agreement on slides with high conﬁdence GT (n 5 92) . The use of the AI tool led to improved performance by readers, interobserver agreement increased from 75.0% for digital manual read to 83.7% for AI-assisted review, and scoring accuracy improved from 85.3% to 88.0% . For the distinction of HER2 0 from 11 cases (n 5 58), pathologists supported by AI showed signiﬁcantly higher interobserver agreement (69.8% without AI v 87.4% with AI) and accuracy (81.9% without AI v 88.8% with AI) . |\n| CONCLUSION | This study demonstrated utility of a fully automated AI solution to aid in scoring HER2 IHC accurately according toASCO/CAP 2018/2023 guidelines. Pathologists supported by AI showed improvements in HER2 IHC scoring consistency and accuracy, especially for distinguishing HER2 0 from 11 cases. This AI solution could be used by pathologists as a decision support tool for enhancing reproducibility and consistency of HER2 scoring and particularly for identifying HER2-low breast cancers. |\n\nACCOMPANYING CONTENT  \n Data Sharing Statement  \n Data Supplement  \nAccepted August 16, 2024 Published October 11, 2024  \nJCO Precis Oncol 8:e2400353 © 2024 by American Society of Clinical Oncology  \nCreative Commons Attribution Non-Commercial No Derivatives 4.0 License  \nINTRODUCTION  \nThe standard-of-care evaluation of human epidermal growth factor receptor 2 (HER2) in breast cancer includes immunohistochemistry (IHC) to assess protein overexpression and in situ hybridization (ISH) to determine gene ampliﬁcation. ASCO and College of American Pathologists (CAP) published guidelines for HER2 testing—ﬁrst in 2007 and updated in 2013, 2018, and 2023—that enhanced standardization of HER2 testing in clinical practice.1 Since the available HER2-targeted therapy was beneﬁcial only to patients with HER2-positive disease, the testing guidelines provided  \nrecommendations for clearly distinguishing a negative from a positive result. The categorization of the HER2 testing result until now has therefore been essentially binary.  \nThe results of the DESTINY-Breast 04 clinical trial reported by Modi et al2 showed the need to identify patients with low levels of HER2 protein expression and to distinguish 0 from 11 scores. In that trial, patients with metastatic breast cancer that was HER2-nega","cbCaigVUKtOfnlwz","https://ap.wps.com/l/cbCaigVUKtOfnlwz","pdf",1201120,"English","# Abstract\n## Purpose\n## Materials and Methods\n## Results\n## Conclusion\n# Introduction\n# Context\n## Key Objective\n## Knowledge Generated\n## Relevance","[{\"question\":\"What problem does the study address in HER2 testing?\",\"answer\":\"The study targets the need for more accurate and reproducible HER2 immunohistochemistry (IHC) scoring to support effective HER2-targeted treatment decisions, especially for HER2-low cancers.\"},{\"question\":\"How was the AI solution evaluated in the multireader study?\",\"answer\":\"A two-arm multireader design assessed 120 HER2 IHC whole-slide images, with four surgical pathologists scoring both without and with AI support. Comparisons were made against high-confidence ground truth derived from expert consensus following ASCO/CAP guidelines.\"},{\"question\":\"What improvements did the AI tool produce for pathologists?\",\"answer\":\"AI assistance increased interobserver agreement and scoring accuracy versus digital manual review, with particularly strong improvements for distinguishing HER2 0 from HER2 1+ cases.\"}]","Fully Automated Artificial Intelligence Solution for Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Scoring in Breast Cancer - A Multireader Study | PDF",1790016938,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59c3e5e458364652a46cb0869fba8fd5.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36dbdc019eab2cc0d7b429bb2a083f89.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a27b31af2c36141d8e36f0c913e56c1d.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2c606ec0f61c41ba14eb4c7c190c73e.webp",980,1311]